8-K: bioAffinity Technologies Reports Strong Q1 2025 Results Driven by CyPath Lung Sales

bioAffinity Technologies reports a 276% year-over-year increase in CyPath Lung sales, contributing to $1.9 million in revenue for the first quarter of 2025.

Summary

• bioAffinity Technologies reported its financial results for the first quarter of 2025.
• Revenue for the quarter was $1.9 million, primarily from patient service fees, histology services, and medical director fees.
• CyPath Lung sales increased by 276% year-over-year.
• Operating expenses were $4.5 million, compared to $4.4 million in the first quarter of 2024.
• The company implemented strategic actions expected to reduce annual costs by approximately $3.8 million.
• Net loss for the quarter was $2.7 million, or $0.16 per share, compared to a net loss of $2.0 million, or $0.20 per share, for the first quarter of 2024.
• Cash and cash equivalents as of March 31, 2025, were $0.4 million.
• Subsequent to the end of 2024, bioAffinity Technologies raised gross proceeds of $1.4 million through the inducement of warrant exercises in February 2025 and $3.3 million in a public offering in May 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong sales growth of CyPath Lung and cost reduction initiatives, but tempered by the net loss and decrease in cash reserves. The successful capital raises are also a positive factor.

Positives

• Significant growth in CyPath Lung sales indicates increasing market adoption.
• Cost reduction initiatives are expected to improve profitability.
• Improvements in CyPath Lung processing enhance efficiency and reduce costs.
• Successful capital raising activities strengthen the company's financial position.
• Patient case studies highlight the clinical utility of CyPath Lung.

Negatives

• The company experienced a net loss of $2.7 million for the quarter.
• Cash and cash equivalents decreased to $0.4 million as of March 31, 2025.
• Selling, general, and administrative expenses increased compared to the same period last year.

Risks

• The company's ability to reduce costs while expanding sales of high-margin diagnostics is subject to risk.
• The company's ability to accelerate the commercial growth of CyPath Lung is subject to risk.
• The company's ability to advance new diagnostics for diseases like COPD and asthma is subject to risk.
• The company's future performance is subject to various risks and uncertainties, many of which are difficult to predict.

Future Outlook

The company aims to expand access to CyPath Lung for patients at risk of lung cancer and advance new diagnostics for diseases like COPD and asthma. Strategic actions are expected to reduce annual costs by approximately $3.8 million while expanding sales focus on high-margin diagnostics like CyPath Lung. International patents are expected to expand CyPath Lung's global commercialization potential.

Management Comments

• We began 2025 with strong momentum, delivering 276% year-over-year growth in CyPath Lung sales and expanding our commercial footprint across the U.S., said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies.
• Our first-quarter results reflect both the growing demand for our noninvasive lung cancer diagnostic and the successful execution of our strategy to focus on high-value services and operational efficiency.
• These targeted actions will reduce costs approximately $3.8 million annually and accelerate the commercial growth of CyPath Lung.
• As we move forward, we're encouraged by the clinical and economic validation that supports our growth, including recent operational enhancements that have increased our test throughput by 50% and lowered per-test cost by over 25%.
• With every test delivered, we're improving outcomes for patients and delivering value to our shareholders.

Industry Context

The announcement reflects a growing trend in the biotechnology industry towards non-invasive diagnostic tests, particularly in the field of oncology. The focus on early detection and personalized medicine is driving demand for innovative solutions like CyPath Lung.

Comparison to Industry Standards

• The 276% year-over-year growth in CyPath Lung sales is significant compared to the average growth rates of diagnostic companies.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) are also focused on early cancer detection through non-invasive methods, but bioAffinity's specific focus on lung cancer provides a niche market.
• The cost reduction initiatives, aiming for $3.8 million annually, are crucial for improving profitability and competitiveness in the diagnostic market.

Stakeholder Impact

• Shareholders may benefit from the company's growth strategy and cost reduction efforts.
• Patients may benefit from increased access to CyPath Lung and new diagnostic tests.
• Employees may be affected by the company's cost reduction initiatives, including potential labor cost reductions.

Next Steps

• Expand access to CyPath Lung for patients at risk of lung cancer.
• Advance new diagnostics for diseases like COPD and asthma.
• Continue implementing strategic actions to reduce annual costs by approximately $3.8 million.
• Focus on high-margin diagnostics like CyPath Lung.

Key Dates

Keywords

CyPath Lung, lung cancer, diagnostics, bioAffinity Technologies, financial results, biotechnology